On March 5, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), reported that management will present at two investor conferences in March (Press release, UroGen Pharma, MAR 5, 2019, View Source [SID1234533973]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 39th Annual Health Care Conference
Tuesday, March 12th
11:20AM Eastern Time
Boston, MA
Oppenheimer 29th Annual Healthcare Conference
Tuesday, March 19th
9:10AM Eastern Time
New York, NY
A live audio webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.

On March 5, 2019 Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, reported that management will present at the following March investor conferences (Press release, Epizyme, MAR 5, 2019, View Source [SID1234533972]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:20 a.m. ET in Boston; and,
Oppenheimer & Co. 29th Annual Healthcare Conference at 11:00 a.m. ET on March 20, 2019 in New York City.
Live webcasts will be available in the investor section of the company’s website at www.epizyme.com. The webcasts also will be archived for 60 days following the call and presentation.

On March 5, 2019 Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that Gavin Bennett, Ph.D., Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London (Press release, Bicycle Therapeutics, MAR 5, 2019, View Source [SID1234533971]). The presentation, focused on Bicycle’s pre-clinical BT5528 program for the treatment of solid tumours, will take place at 11:30 a.m. GMT on Wednesday, March 6.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We expect BT5528 to be Bicycle’s second clinical oncology product candidate and will build on the ongoing Phase I/IIa clinical study with BT1718. We are very excited about its potential to treat solid tumours," said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. "Preclinical data from our BT5528 program shows target-dependent anti-tumour activity across a range of EphA2-expressing tumour models without evidence of the profound toxicity seen with previous clinical-stage antibody drug conjugates targeting EphA2."

Dr. Bennett has also been invited to chair the "Discovery" track sessions at the conference.

On March 5, 2019 Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will present a company overview at the 39th Annual Cowen & Co.Health Care Conference on Tuesday, March 12, 2019 at 8:40 a.m. ET (Press release, Blueprint Medicines, MAR 5, 2019, Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference [SID1234533970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

On March 5, 2019 Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, reported that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the Cowen and Company 39th Annual Health Care Conference at 8:00 am ET on Tuesday, March 12, 2019 in Boston, MA (Press release, Alder Biopharmaceuticals, MAR 5, 2019, https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-present-cowen-and-company-39th-annual [SID1234533969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live on the Events & Presentations page of the Investors section of Alder’s website at View Source, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for at least 30 days after the live event concludes.